Duration of Tamoxifen use and the Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers

Journal article

J. Gronwald, A. Robidoux, C. Kim-Sing, N. Tung, Henry T. Lynch, W. D. Foulkes and S. et al Manoukian

Breast Cancer Research and Treatment, Vol.146(2), pp.421-427

07/2014

PMID: 24951267

Metrics

4 Record Views

Title: Duration of Tamoxifen use and the Risk of Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Creators: J. Gronwald (Author)
A. Robidoux (Author)
C. Kim-Sing (Author)
N. Tung (Author)
Henry T. Lynch (Author) - Creighton University
W. D. Foulkes (Author)
S. et al Manoukian (Author)
Additional links: http://doi.org/10.1007/s10549-014-3026-3
Publication Details: Breast Cancer Research and Treatment, Vol.146(2), pp.421-427
Number of pages: 421-427
Identifiers: 991005931947402656
Academic Unit: School of Medicine; Prev. Medicine & Public Health
Resource Type: Journal article